Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Engensis (VM202) long-term safety extension in painful diabetic peripheral neuropathy
NCT04055090Phase 3Completed
- Sponsor
- Helixmith
- Start
- Feb 2019
- Primary completion
- Jul 2019
- Modality
- Gene Editing, Gene Silencing, Plasmid DNA
- Countries
- 1
01
Overview
A Phase 3 trial of Engensis in diabetic peripheral neuropathy (DPN), sponsored by Helixmith. Started Feb 2019; status: completed.
02
Drugs
Engensis
03
Conditions
diabetic peripheral neuropathy (DPN)
Beyond the preview
Go deeper on NCT04055090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04055090.